Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Short term Debt: 2012-2024

Historic Short term Debt for Ptc Therapeutics (PTCT) over the last 9 years, with Dec 2024 value amounting to $257.8 million.

  • Ptc Therapeutics' Short term Debt rose 11.14% to $286.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.3 million, marking a year-over-year increase of 11.14%. This contributed to the annual value of $257.8 million for FY2024, which is 32.68% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Short term Debt of $257.8 million as of FY2024, which was up 32.68% from $194.3 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Short term Debt registered a high of $257.8 million during FY2024, and its lowest value of $21.0 million during FY2020.
  • In the last 3 years, Ptc Therapeutics' Short term Debt had a median value of $194.3 million in 2023 and averaged $174.8 million.
  • Per our database at Business Quant, Ptc Therapeutics' Short term Debt soared by 611.32% in 2021 and then plummeted by 51.75% in 2022.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Short term Debt stood at $21.0 million in 2020, then skyrocketed by 611.32% to $149.5 million in 2021, then crashed by 51.75% to $72.1 million in 2022, then spiked by 169.32% to $194.3 million in 2023, then skyrocketed by 32.68% to $257.8 million in 2024.